, Volume 62, Issue 3, pp 297-303

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Intracavitary levels of VEGF, bFGF, IL-8 and IL-12 were evaluated by ELISA in 45 patients, 7 with recurrent anaplastic astrocytoma (rAA), 12 with glioblastoma (GBM) and 26 with recurrent glioblastoma (rGBM). In 25 patients plasma levels of the molecules were also quantitated. Twenty-three healthy controls were also studied for plasma concentrations of the same molecules.

Plasma levels of VEGF (mean 33.89 ± 6.71 pg/ml) and bFGF (mean 11.1 ± 3.24 pg/ml) were higher in patients than in controls (mean 16.78 ± 3.7 pg/ml for VEGF, mean 0.21 ± 0.09 pg/ml for bFGF) (p = 0.04 and p = 0.001, respectively) while plasma IL-12 levels were lower (mean 45.6 ± 1.5 pg/ml in patients, mean 79.7 ± 1.3 pg/ml in controls) (p = 0.009).

Intracavitary VEGF levels were 5–53.307 fold higher (mean 90,900 ± 24,789 pg/ml) than in the corresponding plasma. Also IL-8 concentrations were higher in intracavitary fluid (mean 6,349.76 ± 1,460.93 pg/ml) than in plasma (mean 43.44 ± 24.82 pg/ml). Maximum VEGF levels were found in tumor fluid of recurrent glioblastoma patients (mean 147,678 ± 39,903 pg/ml), intermediate levels in glioblastoma patients (mean 20,322 ± 11,892 pg/ml) and lower levels in rAA patients (mean 9,111 ± 5,789 pg/ml). The data also suggest that higher intracavitary levels of VEGF and IL-8, and lower IL-12 levels, may be correlated with shorter adjunctive survival times, but more data will need to be collected to establish this correlation clearly.